Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed high-grade glioma (WHO grade III or IV)
• Must be scheduled to receive standard first-line therapy (cranial radiotherapy and temozolomide)
• PATIENT CHARACTERISTICS:
• ANC ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Creatinine ≤ 1.7 mg/dL
• Bilirubin ≤ 1.5 mg/dL
• Transaminases ≤ 4 times upper limit of normal
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other malignancy within the past 5 years except curatively treated carcinoma in situ or basal cell carcinoma of the skin
• PRIOR CONCURRENT THERAPY:
• No prior hormonal therapy for brain tumor
• No prior biological agents (including immunotoxins, immunoconjugates, antisense agents, peptide receptor antagonists, interferons, interleukins, tumor-infiltrating lymphocytes, lymphokine-activated killer cells, or gene therapy)
• No prior immunotherapy
• No prior chemotherapy
• No prior radiotherapy, including cranial radiotherapy
• Concurrent glucocorticoid therapy allowed
• No concurrent carbamazepine
• No other concurrent experimental therapy
• No other concurrent cytotoxic therapy